Lola Manterola, President of CRIS Cancer Foundation, shared a post on LinkedIn:
“The story of how from CRIS Cancer Foundation we began to finance the first vaccine to prevent lung cancer by Dr. Sarah Blagden has a great protagonist: time.
Without going into great detail, let’s just say that Dr Blagden’s work in the University of Oxford – detailed in this lengthy article in The Sunday The Times – had reached a point where she needed to set in motion a decisive phase and her funder was stuck in decision-making processes.
In CRIS Cancer Foundation we learned about the situation and without thinking about it we volunteered.
Who doesn’t want to support research that can open doors to vaccines that prevent, not only lung cancer, but cancer in general?
Warn! Prevent it from appearing!
The time of science is always what it is, urgent, and we know it well, so if there is one thing we are especially proud of, it is that we are a fast organization, which prioritizes execution over bureaucracy and endless paperwork. We want to be there when needed.
Today Sarah Blagden and his team at the University of Oxford are already working on a vaccine that teaches our own immune system to recognize the incipient stages of lung cancer and prevent it from developing. A vaccine that he hopes to have ready in less than ten years.”
